Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Collaborating to Treat Rare Diseases
Posted on November 16th, 2016 by Christy J. Wilson in Pharma R&D
There are about 7,000 diseases out there that are considered “rare,” but they actually affect hundreds of millions of people worldwide – nearly half of whom are children. The vast majority of them have no approved drug treatment. The reason is because developing new drugs is so terribly costly for pharmaceutical companies that it is seldom economically feasible to focus on treatments that only help a small number of people.
It’s precisely because R&D is so expensive that drug re-purposing is becoming a common way for companies to bring “new” drugs to market. And, thanks to a combination of increasingly sophisticated data, analytical tools and growing interest in precision medicine, drug re-purposing is opening up new avenues for developing rare disease treatments. However, to find success in targeting rare diseases, pharma companies must welcome collaborative efforts – with bioinformatics companies, academic institutions and beyond.
To find out more about how innovative partnerships can tackle rare disease, read Tim Hoctor’s article Repurposing Drugs for Rare Diseases: Collaboration is Key.
All opinions shared in this post are the author’s own.
R&D Solutions for Pharma & Life SciencesWe're happy to discuss your needs and show you how Elsevier's Solution can help.
Christy J. Wilson
Sr. Director, Pharma and Biotech Segment
Connect on LinkedIn
Follow on Twitter
- So-Called Rare Diseases Are Too Common to Ignore
- What Are Best Practices in Literature Monitoring for Top-performing Pharma Companies?
- Gaining the Competitive Advantage
- Broadening the Field of Research While Staying Focused
- FDA Regulations Reform? Risks and Benefit for the Approval Process of New Drugs